Sponsored by

Here's why ​Sarepta Therapeutics is consolidating in Massachusetts

"Optimizing efficiency” is a key phrase right now, as the company’s future is very much up in the air as it awaits an FDA approval decision on its drug for Duchenne muscular dystrophy.

​Eight new things keeping Vertex Pharmaceuticals up at night in 2016

The Boston-based drugmaker revealed as potential “risk factors” in the company’s most recent annual report several items that were notably absent from last year’s report.

Epizyme lays out plans to have its cancer drug approved as soon as 2018

The plan announced this morning is the first time the company has given a timeline for approval of tazemetostat.

State hearing on widely-varied hospital costs offers few solutions

Solutions on how to close the gap hospitals charge for the same service are few and far between, and legislators are running out of time.

​Tim Cook, Larry Page and Elon Musk attend secret Trump meeting

Theranos ran blood tests despite knowing of quality problems: report